Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung… - The Lancet, 2020 - thelancet.com
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
[引用][C] Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients …
EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung… - The Lancet, 2020 - cir.nii.ac.jp
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based
chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative …
chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji… - …, 2020 - epub.ub.uni-muenchen.de
Background: Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji… - The …, 2020 - ohsu.elsevierpure.com
Background: Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, Z Hong, CH Barrios, S Saji, KH Jung… - The Lancet, 2020 - hal.science
Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC)
include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 …
include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji… - Lancet (London …, 2020 - europepmc.org
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung… - The Lancet, 2020 - Elsevier
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung… - 2020 - ir.ymlib.yonsei.ac.kr
Background: Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA MITTENDORF, H ZHANG, CH BARRIOS, S SAJI… - 2020 - observatorio.fm.usp.br
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios… - Lancet (London …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …